Agilent Technologies (A) has been active on several fronts recently, from new collaborations in biopharma analytics to the launch of its 16850 Series portable logic analyzers, giving investors fresh context for assessing the stock.

Despite fresh product launches and new biopharma collaborations shaping sentiment, Agilent’s share price has eased recently. The 30-day share price return is down 4.05% and the year-to-date share price return is down 18.27%, while the 1-year total shareholder return is 1.92%. This points to fading momentum in the shorter term but a modest positive outcome for patient holders.

If this mix of life sciences tools and digital analytics interests you, it can be worth seeing what else is moving in related fields and checking out 33 healthcare AI stocks

With recent returns under pressure but analysts’ targets and intrinsic estimates sitting above the current US$112.74 share price, the key question for you is whether Agilent is trading below its potential or if the market is already pricing in future growth.

Most Popular Narrative: 29.8% Undervalued

Agilent's most followed narrative sets a fair value of $160.69 per share, well above the last close at $112.74. This frames the current debate around upside versus execution risk.

Strategic investments in higher margin recurring revenue streams including consumables, software, services, and digital platforms are gaining traction, with CrossLab and services delivering consistent mid single digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.

Curious what justifies that higher fair value. The narrative leans heavily on compounding revenue, rising margins, and a future earnings profile that assumes the model keeps working at scale.

Result: Fair Value of $160.69 (UNDERVALUED)

However, you also need to weigh tariff and supply chain pressures that could squeeze margins, as well as tighter research budgets that could cool demand in key end markets.

Next Steps

Given this mix of cautious signals and optimism, it makes sense to move quickly, review the underlying drivers yourself, and weigh the 4 key rewards.

Looking for more investment ideas?

If Agilent has sharpened your thinking, do not stop here. Broaden your watchlist with a few focused stock ideas built from clear, data driven filters.

• Target stability first by scanning 68 resilient stocks with low risk scores to help keep surprises in check while you concentrate on your bigger decisions.
• Hunt for value by reviewing screener containing 23 high quality undiscovered gems that many investors may still be overlooking despite solid underlying fundamentals.
• Strengthen your core holdings by focusing on the solid balance sheet and fundamentals stocks screener (45 results) so you are not leaning on companies with fragile finances.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.